PHYSICIAN-FACING SCIENTIFIC PORTFOLIO

Three platforms.
One wound healing cascade.

Antimicrobial matrices, human placental allografts, and collagen dressing systems — each targeting distinct failure points in the chronic wound proteolytic cascade.

30×
MMP activity: chronic vs. acute wounds
60–90%
of chronic wounds harbor biofilm
99.99%
Microlyte antimicrobial efficacy
91%
of refractory wounds healed / improved at 12 wk
Overview

Three platforms. Each targets a distinct failure point.

Chronic wounds stall in a self-amplifying proteolytic cycle. Each of our three platforms addresses a different driver — together, they reset the cascade.

Neutralize

Collagen Dressings

Sacrificial substrate sequesters excess MMPs. Restores protease : anti-protease balance. Enables inflammation → proliferation phase transition.

Protect

Microlyte SAM

Sub-cytotoxic silver breaks the biofilm cycle. Bioresorbable scaffold supports granulation. No removal trauma.

Regenerate

Amniotic Membrane

Multi-layer biological pharmacy: 25+ growth factors, HC-HA/PTX3 complex, native ECM scaffold.

Antimicrobial
Microlyte SAM
FDA 510(k) K153756
Tri-Layer
Tri-Membrane Wrap
A-C-A, escalation product
Dual-Layer
Membrane Wrap
2× ECM + GF payload
Single Amnion
Membrane Wrap Lite
Cost-effective entry
The Chronic Wound Problem

Why chronic wounds fail to heal.

Chronic wounds are locked in a self-amplifying proteolytic cycle. MMPs at 30× physiological levels destroy growth factors, native ECM, and their own inhibitors. Biofilm maintains inflammation. Senescent fibroblasts amplify the cascade.

MMP Overexpression

MMP-9 in poor healers: 17× higher. PDGF degraded within 2 hours.

Biofilm Persistence

60–90% of chronic wounds. EPS matrix shields bacteria from immunity.

Growth Factor Sink

Proteolytic environment degrades growth factors before signaling can occur.

Cellular Senescence

>15% senescent cells = treatment-resistant. SASP amplifies MMPs.

Integrated Treatment Logic

Sequential cascade reset

Neutralize

Collagen Dressings

Sacrificial substrate sequesters excess MMPs. Restores protease : anti-protease balance.

Protect

Microlyte SAM

Sub-cytotoxic silver breaks biofilm cycle. Bioresorbable scaffold supports granulation.

Regenerate

Amniotic Membrane

25+ growth factors, HC-HA/PTX3 complex, native ECM scaffold.

Human Placental Allografts

Amniotic membrane — layer architecture.

Over 25 growth factors, anti-inflammatory cytokines, and TIMPs in native ECM. Each layer contributes distinct biology to wound healing.

Amnion

Basement membrane: Type IV Collagen, Laminin-1/5, Fibronectin

Growth factors: EGF, FGF-2, PDGF-AA/BB, VEGF, KGF, HGF, TGF-α, IGF-1

Anti-inflammatory: HC-HA/PTX3, IL-10, IL-1Ra, PGE2, TIMP-1/2/3/4

Re-epithelialization scaffold
Keratinocyte migration · immune privilege

Intermediate (Spongy) Layer

Composition: HA >4,000 kDa · Type III Collagen · Decorin · Biglycan · Proteoglycans

Function: Growth factor reservoir · anti-fibrotic TGF-β sequestration via decorin

Sustained-release depot
Hydrated GF reservoir

Chorion

Collagen matrix: Types I, III, IV, V, VI · Fibronectin · Tenascin

Structure: Dense reticular network · trophoblast growth factor production

Function: Mechanical backbone · slow-diffusion sustained release

Structural persistence
Extended residence time
Product Portfolio — By Complexity

HC-HA/PTX3 anti-inflammatory master switch

HA >4,000 kDa + heavy chain 1 via TSG-6 + pentraxin 3 drives apoptosis of activated neutrophils/macrophages, M2 polarization, and Treg expansion. Downregulates TGF-β1 mRNA + receptors I/II/III and activates BMP — reverting myofibroblasts and attenuating nociceptive excitability.

Single Amnion

Membrane Wrap Lite

Best for: shallow DFUs, partial-thickness VLUs

Basement-membrane scaffold + growth-factor monolayer. Cost-effective entry point.

Dual-Layer Amnion

Membrane Wrap

Best for: moderate chronic wounds, deeper partial-thickness

2× ECM + growth-factor payload. Enhanced structural integrity and sustained GF kinetics.

Tri-Layer (A-C-A)

Tri-Membrane Wrap

Best for: failed prior grafts, deep full-thickness, high-risk patients

A-C-A sandwich: highest ECM concentration. Dense chorion collagen between two amnion layers. Escalation product.

FDA 510(k) K153756 HCPCS A2005 Fully Synthetic

Microlyte® SAMsub-cytotoxic silver.

PEM nanofilm on bioresorbable PVA. 50–100× less silver than conventional dressings. Equivalent 99.99% antimicrobial kill via intimate surface-contact delivery.

Conventional Dressing

Rigid silver dressing
Dead space → bacterial colonization
~12 mg/100 cm² · above cytotoxic threshold
High silver / low contact

Cytotoxic to fibroblasts & keratinocytes

Microlyte SAM

Ultra-thin PVA conforms to micro-contours
Full contact → zero dead space
~1.6 mg/100 cm² · sub-cytotoxic, 50–100× less
Low silver / full contact

99.99% kill · 72+ hrs · bioresorbable 7 days

Polymer science

PEM nanofilm architecture

Layer-by-layer cationic/anionic polymer assembly. Cationic termination enhances cell attachment, ECM production, and actin organization via electrostatic interaction with proteoglycans.

PVA cytophilicity

Hydroxyl (–OH) groups hydrogen-bond with ECM proteins (fibronectin, vitronectin). Presents integrin-binding domains. Mechanical properties mimic native soft tissue.

Bioresorbable design

~20 µm PVA resorbs in 7 days. No removal → no granulation disruption. Integrates without foreign-body response. 4-year shelf life.

Clinical Evidence
91%
Healed or improved at 12 weeks (Manning, n=32)
0%
SSI in diabetic foot surgery (Chatelain, n=22)
73%
Average wound area reduction
All wounds treatment-refractory · mean 40 weeks stalled · unresponsive to prior antimicrobials
Collagen Program

Type I Collagen — sacrificial substrate & bioactive signal.

Exogenous collagen reverses the proteolytic cycle by diverting MMP activity from endogenous ECM. As it degrades, it releases bioactive matrikines that actively drive granulation and fibroblast chemotaxis.

Chronic Wound

MMPs: 30× physiologic · GFs: degraded · ECM: destroyed · TIMPs: gone. Self-amplifying cycle.

Exogenous Collagen

Sacrificial MMP substrate. Diverts proteases from native ECM. Restores MMP : TIMP ratio.

Healing Wound

Phase transition enabled. GFs preserved · ECM intact. Proliferation phase initiated.

Collagen Degradation = Bioactive Matrikines
GHK-Cu tripeptide

Promotes collagen synthesis · upregulates VEGF & bFGF expression.

RGD sequences (exposed via MMP)

Integrin α1β1, α2β1 binding · fibroblast chemotaxis.

α11β1 by day 7: granulation + tensile strength · DDR1/2 → β1-integrin & α-SMA

Clinical evidence — two pathways

Post-op incision

Reimbursable during the global surgical period.

59%
SSI reduction (n = 5,335)
0%
SSI in spinal surgery (n = 54)
Conservative wound care

Full-thickness or wounds stalled >4 weeks.

53%
Higher healing rate (meta-analysis, n = 961)
82%
Complete DFU healing (RCT)
Clinical Decision Framework

Product selection by wound presentation.

Matching the right platform to the dominant failure mode of the wound in front of you.

Wound PresentationPrimary ProductMechanismKey Evidence
Post-op surgical incision Collagen dressing Sacrificial MMP substrate, hemostasis, SSI prevention 59% SSI reduction (n = 5,335)
Active biofilm / infection risk Microlyte SAM (A2005) Sub-cytotoxic ionic silver, 99.99% kill, 72+ hrs 91% healed or improved at 12 wk
Shallow / early chronic Membrane Wrap Lite Single-amnion barrier, ECM scaffold, GF delivery BM re-epithelialization template
Standard DFU / VLU Membrane Wrap (Dual-layer) 2× ECM payload, structural persistence Sustained GF, dual-layer kinetics
Recalcitrant / failed grafts Tri-Membrane Wrap (A-C-A) Highest ECM concentration, chorion sandwich Escalation — max biological payload
Compliance Infrastructure

CheckMyWoundCareNotes.com

Automated compliance review against LCD L35041, A54117, MPIM 3.6.2.2, SSA 1862(a)(1)(A). Pre-submission gap detection, FPS pattern flagging, and corrective-language generation.

Pre-submission review

Upload notes → automated check against LCD criteria, documentation requirements, and frequency limits.

FPS pattern detection

Flags cloned documentation, utilization outliers, wastage patterns, and product-selection anomalies.

Corrective language

LCD-aligned clinical prose generated from documented findings. Audit-defensible.

The only wound care partner delivering product + compliance + science in a single relationship.

Let's talk science

Go deeper with our clinical team.

Schedule a scientific review — we'll walk your team through each platform, LCD alignment, and the evidence base for the wounds you see most.